Not Yet RecruitingPhase 3

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

China450 participantsStarted 2026-04-30

Plain-language summary

The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.

Who can participate

Age range50 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 50 to 85 years old (inclusive of 50 and 85 years old)
✓. Meets the Western medical diagnostic criteria for neovascular age-related macular degeneration
✓. Meets the TCM syndrome differentiation criteria for Qi-Yin Deficiency with Phlegm-Blood Stasis Intermingling Syndrome
✓. The study eye is diagnosed with nAMD and the disease is in the active phase
✓. BCVA of the study eye assessed by the ETDRS visual acuity chart ranges from 25 to 78 letters
✓. Voluntarily participates in the clinical trial, signs the ICF, and is able to understand and comply with the trial procedures

Exclusion criteria

✕. The study eye is complicated with pathologic myopia, high myopia, or secondary MNV caused by other definite diseases, glaucoma, diabetic retinopathy , retinal artery/vein occlusion , optic neuropathy (optic neuritis, optic atrophy, papilledema), macular hole, acute phase of intraocular inflammation, or other ocular diseases
✕. Patients with pure PED in the study eye
✕. Patients with subfoveal structural destruction or subfoveal fibrosis/scars/RPE tear/GA in the study eye
✕. Patients whose FP of the study eye shows a total macular lesion area \> 9 disc areas (total lesion area is defined as the sum of the areas of MNV, atrophy, scars, and fibrosis); or patients whose FP of the study eye shows a maximum macular hemorrhage area \> 4 disc areas
✕. Patients with CRT ≥ 700 μm in the study eye as assessed by OCT
✕. Patients with opaque refractive media (e.g., vitreous hemorrhage, cataract) in the study eye precluding adequate visualization of the fundus, or with a history of vitrectomy
✕. Patients planning to undergo any intraocular surgery on the study eye during the trial period
✕. Patients who received pharmacologic treatment for nAMD within 2 weeks prior to randomization

What they're measuring

Proportion of participants with ranibizumab injections

Timeframe: 24 weeks

Trial details

NCT IDNCT07269769

SponsorTasly Pharmaceutical Group Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2031-12-31

Contact for this trial

Rui Liu

022-86343626 liurui383@taslypharma.com

View on ClinicalTrials.gov More AMD trials